No immediate trading action warranted. Monitor the Q1 FY2027 earnings call for any guidance updates or commentary on underlying segment performance under the new structure.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $71.28entry
- T+1 · 5mo ago +5.05%α +4.82% · $74.88
- T+5 · 5mo ago +9.71%α +9.14% · $78.20
- T+20 · 4mo ago +5.25%α +3.39% · $75.02
- T+60 · 3mo ago +44.60%α +40.60% · $103.07
Price Chart
How similar events traded
Executive Summary
Haemonetics announced a change to its reportable segment structure, combining the Plasma and Blood Center segments into a single 'Apheresis' segment and renaming the Hospital segment to 'MedSurg', effective Q1 FY2027. The company posted recast historical revenue and a recast of previously issued FY2027 guidance to align with the new structure, but explicitly stated it is not reaffirming or updating that guidance. This is a routine administrative reorganization with no new financial data or change in outlook.
Key Facts
- Haemonetics transitions from three reportable segments to two: Apheresis (combined Plasma + Blood Center) and MedSurg (renamed from Hospital).
- New segment structure effective Q1 FY2027, which began March 29, 2026.
- Company posted recast historical revenue for FY2024-2026 and recast FY2027 guidance on its IR website.
- Company explicitly states the recast is not a reaffirmation or update of previously issued FY2027 guidance.
- No financial figures, guidance changes, or material business developments were disclosed.
Financial Impact
No financial impact, segment reclassification only, no new numbers or guidance changes.
Risk Factors
- Segment reclassification may cause temporary confusion in financial models until analysts adjust.
- No reaffirmation of guidance could be interpreted negatively if the market was expecting an update.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000313143-26-000057 |
| Exhibit: ex991-pressrelease652026.htm | 0000313143-26-000057 |
| Document: 0000313143-26-000057-index-headers.html | 0000313143-26-000057 |
| Document: 0000313143-26-000057-index.html | 0000313143-26-000057 |
| Document: 0000313143-26-000057.txt | 0000313143-26-000057 |
Track record
14 reports on HAE
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +2.44% at T+5 after the Oct 20, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $122.71 Now $121.34 −1.12% settles Nov 19
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $124.11 to $122.71 Now $121.34 −2.23% ▼ −1.13% −4.42% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $117.11 to $119.97 Now $121.34 +3.61% ▲ +2.44% +2.89% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $118.21 to $119.97 Now $121.34 +2.65% ▲ +1.49% +1.41% vs SPY
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $122.06 to $118.73 Now $121.34 −0.59% ▼ −2.73% −1.23% vs SPY
- Oct 8, 20265w ago 8-K Neutral 4/10 Entry $119.47 to $121.29 Now $121.34 +1.57% ▲ +1.52% +1.80% vs SPY
- Sep 30, 20266w ago Press Release Neutral 1/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Sep 30, 20266w ago Court Ruling Neutral 3/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Aug 18, 202612w ago 8-K Neutral 3/10 Entry $104.65 to $108.32 Now $121.34 +15.95% ▲ +3.51% +3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers